Boston Scientific Faces Weeks-Long Disruption From Cyberattack as Analysts Eye Q3 Impact
Boston Scientific reports a cyberattack detected August 25, 2026, disrupting systems, delaying product shipments worldwide. Full scope still unknown.
/ 7 items
#BSX↓
Edwards’ Ecliptis Wins FDA Clearance, Challenges AtriCure in Surgical LAA Market
Edwards got FDA OK for heart clip; it enters a market led by AtriCure, adding competition but not changing the outlook much.
Edwards Lifesciences Gets Big Boost as CMS Expands TAVR Coverage to Asymptomatic Patients
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
Boston Scientific Drops $1.5B on Game-Changing Nickel-Free Heart Valve Tech + $2B Buyback
Boston Scientific invests $1.5B in MiRus for new heart valve tech and launches $2B buyback to boost shares and growth.
Wells Fargo Calls Boston Scientific’s WATCHMAN Trial “Good, Not Great”
Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Boston Scientific Shares Drop Despite Strong Q4 as 2026 Outlook Disappoints
Boston Scientific (BSX) reports strong Q4 2025 earnings but shares fall over 10% on modest 2026 guidance. Revenue growth expected to slow to 10-11% from 15.8% in 2026.